Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: Retrospective analysis of safety profile and effect on blood coagulation

References

• Beyer J, Wessela S, Hakenberg OW, Kuhlisch E, Halbritter K, Froehner M, et al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. J Thromb Haemost 2009;7:597–604.
   PubMed Web of Science ®Google Scholar
• Secin FP, Jiborn T, Bjartell AS, Fournier G, Salomon L, Abbou CC, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008;53:134–45.
   PubMed Web of Science ®Google Scholar
• Patel T, Kirby W, Hruby G, Benson MC, McKiernan JM, Badani K. Heparin prophylaxis and the risk of venous thromboembolism after robotic-assisted laparoscopic prostatectomy. BJU Int 2011;108:729–32.
   Google Scholar
• Soloway MS. Thromboembolism prophylaxis and total prostatectomy: is pharmacologic therapy required? Eur Urol 2008;53:21–3.
   Google Scholar
• Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol 2013;63:354–63.
   PubMed Web of Science ®Google Scholar
• Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011;9:12–9.
   PubMed Web of Science ®Google Scholar
• Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127:S5–12.
   PubMed Web of Science ®Google Scholar
• Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess 2009;13:55–62.
   PubMed Web of Science ®Google Scholar
• McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009;27:829–46.
   PubMed Web of Science ®Google Scholar
• Melnikova I. The anticoagulant market. Nat Rev Drug Discov 2009;8:353–4.
   PubMed Web of Science ®Google Scholar
• DeFeo K, Hayes C, Chernick M, Ryn JV, Gilmour SK. Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol Ther 2010;10:1001–8.
   PubMed Web of Science ®Google Scholar
• Orvieto MA, Patel VR. Evolution of robot-assisted radical prostatectomy. Scand J Surg 2009;98:76–88.
   PubMed Web of Science ®Google Scholar
• Tagnon HJ, Whitmore WF Jr, Schulman P, Kravitz SC. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer 1953;6:63–7.
   PubMed Web of Science ®Google Scholar
• Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:227–77.
   Web of Science ®Google Scholar
• Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT study. Thromb Haemost 1999;8:879–86.
   Google Scholar
• Yigit E, Gönüllü G, Yücel I, Turgut M, Erdem D, Cakar B. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 2008;19:602–7.
   Google Scholar
• Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, et al. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int 2008;102:1086–91.
   Google Scholar
• Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012;157:653–63.
   PubMed Web of Science ®Google Scholar
• Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomized controlled trials: introducing the “cohort multiple randomized controlled trial” design. BMJ 2010;340:963–7.
   Google Scholar
• Järvinen TLN, Sievänen H, Kannus P, Jokihaara J, Khan KM. The true cost of pharmacological disease prevention. BMJ 2011;342:1006–8.
   Google Scholar
• Wu Y, Makuch RW. Detecting rare adverse events in postmarketing studies: sample size considerations. Drug Inf J 2006;40:89–98.
   Google Scholar
• Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, et al. Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. BJU Int 2012;110:828–33.
   Google Scholar
• Agnelli G. Prevention of venous thromboembolism: prevention of venous thromboembolism in surgical patients. Circulation 2004;110:IV4–IV12.
   PubMed Web of Science ®Google Scholar